

# Verena Steinke-Lange

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1672864/publications.pdf>

Version: 2024-02-01

26  
papers

1,380  
citations

623188

14  
h-index

525886

27  
g-index

29  
all docs

29  
docs citations

29  
times ranked

1555  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adenoma and colorectal cancer risks in Lynch syndrome, Lynch-like syndrome and familial colorectal cancer type X. <i>International Journal of Cancer</i> , 2022, 150, 56-66.	2.3	2
2	Clinical Validity of Circulating Tumor DNA as Prognostic and Predictive Marker for Personalized Colorectal Cancer Patient Management. <i>Cancers</i> , 2022, 14, 851.	1.7	5
3	Long-term chemoprevention in patients with adenomatous polyposis coli: an observational study. <i>Familial Cancer</i> , 2022, 21, 463-472.	0.9	4
4	Splicing analyses for variants in MMR genes: best practice recommendations from the European Mismatch Repair Working Group. <i>European Journal of Human Genetics</i> , 2022, 30, 1051-1059.	1.4	7
5	The "unnatural" history of colorectal cancer in Lynch syndrome: Lessons from colonoscopy surveillance. <i>International Journal of Cancer</i> , 2021, 148, 800-811.	2.3	55
6	Value of upper gastrointestinal endoscopy for gastric cancer surveillance in patients with Lynch syndrome. <i>International Journal of Cancer</i> , 2021, 148, 106-114.	2.3	28
7	Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. <i>European Journal of Cancer</i> , 2021, 148, 124-133.	1.3	11
8	Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. <i>Genetics in Medicine</i> , 2021, 23, 1506-1513.	1.1	290
9	No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2856.	1.0	11
10	Early detection of duodenal cancer by upper gastrointestinal endoscopy in Lynch syndrome. <i>International Journal of Cancer</i> , 2021, 149, 2052-2062.	2.3	4
11	Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. <i>Lancet Oncology</i> , 2021, 22, 1014-1022.	5.1	58
12	Liquid Biopsy Hotspot Variant Assays: Analytical Validation for Application in Residual Disease Detection and Treatment Monitoring. <i>Clinical Chemistry</i> , 2021, 67, 1483-1491.	1.5	7
13	Somatic mosaics in hereditary tumor predisposition syndromes. <i>European Journal of Medical Genetics</i> , 2021, 64, 104360.	0.7	8
14	Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe. <i>European Journal of Medical Genetics</i> , 2021, 64, 104350.	0.7	22
15	Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. <i>Genetics in Medicine</i> , 2020, 22, 15-25.	1.1	365
16	Risk-Reducing Gynecological Surgery in Lynch Syndrome: Results of an International Survey from the Prospective Lynch Syndrome Database. <i>Journal of Clinical Medicine</i> , 2020, 9, 2290.	1.0	12
17	Age-dependent performance of BRAF mutation testing in Lynch syndrome diagnostics. <i>International Journal of Cancer</i> , 2020, 147, 2801-2810.	2.3	17
18	Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome. <i>Gastroenterology</i> , 2020, 158, 1326-1333.	0.6	60

#	ARTICLE	IF	CITATIONS
19	Prevalence of CNV-neutral structural genomic rearrangements in MLH1, MSH2, and PMS2 not detectable in routine NGS diagnostics. <i>Familial Cancer</i> , 2020, 19, 161-167.	0.9	11
20	Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort study. <i>BMC Cancer</i> , 2020, 20, 460.	1.1	32
21	Full-length transcript amplification and sequencing as universal method to test mRNA integrity and biallelic expression in mismatch repair genes. <i>European Journal of Human Genetics</i> , 2019, 27, 1808-1820.	1.4	16
22	Survival by colon cancer stage and screening interval in Lynch syndrome: a prospective Lynch syndrome database report. <i>Hereditary Cancer in Clinical Practice</i> , 2019, 17, 28.	0.6	27
23	The Apparent Genetic Anticipation in PMS2-Associated Lynch Syndrome Families Is Explained by Birth-cohort Effect. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1010-1014.	1.1	6
24	Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report. <i>Hereditary Cancer in Clinical Practice</i> , 2019, 17, 8.	0.6	42
25	Cancer Risks for PMS2-Associated Lynch Syndrome. <i>Journal of Clinical Oncology</i> , 2018, 36, 2961-2968.	0.8	147
26	No Difference in Colorectal Cancer Incidence or Stage at Detection by Colonoscopy Among 3 Countries With Different Lynch Syndrome Surveillance Policies. <i>Gastroenterology</i> , 2018, 155, 1400-1409.e2.	0.6	112